Summary

Hester Biosciences has announced its Q1 FY26 results. The standalone performance shows a decline in divisional product sales and profit, while the consolidated performance shows an increase in divisional product sales and a significant surge in net profit.

Key Highlights

1. 1

   Standalone Divisional Product Sales down by 14%

2. 2

   Standalone Profit down by 7%

3. 3

   Consolidated Divisional Product Sales up by 2%

4. 4

   Consolidated Profit up by 131%

5. 5

   Hester Nepal contributed INR 19.19 million net profit in Q1 FY26

6. 6

   Hester Africa delivered a net profit of INR 55.02 million in Q1 FY26

7. 7

   Animal Healthcare Division recorded a 33% decline in sales

8. 8

   Poultry Healthcare Division recorded a 2% growth